Details: pack, label wording, sources, registration
Duphalac 667 mg/ml, Solution
oral solution, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Hospital rectal retention-enema adjunct for acute hepatic encephalopathy when oral administration is unsafe or inadequate
5.9/10
Weak evidence support
Details →
vetman assessment
Duphalac
×
667 mg/ml, oral solution, human medicine
Assessed clinical scope Dog · Hospital rectal retention-enema adjunct for acute hepatic encephalopathy when oral administration is unsafe or inadequate · Into the rectum
Care setting Monitored hospital care after cleansing enema, with prepared dilution, rectal Foley retention technique, airway/mentation review and serial neurologic and fluid-electrolyte reassessment.
vetman score
5.9/10
Weak evidence support
Evidence confidence: Low
Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026
Off-label use
A plausible emergency HE adjunct supported by expert consensus, but invasive, preparation-sensitive and untested in controlled target-animal outcome trials.
Regulatory and scientific credibility 6.5/10
Exact product identity is strong, but rectal use is absent from its label and from the veterinary comparator label; support is professional consensus rather than a route-specific regulatory dossier.
Clinical efficacy 5.5/10
The acidification mechanism and small-animal emergency consensus are plausible, but no controlled dog/cat outcome trial or exact-product rectal study establishes neurologic benefit or superiority.
Safety and tolerability 6.0/10
Systemic exposure is minimal, but the exact rectal route lacks target-animal safety data and is used in unstable neurologic patients; mucosal technique, retention, fluid/electrolyte loss and aspiration/mentation context require close oversight.
Clinical practicality 5.5/10
The protocol is feasible in hospital but requires cleansing, exact 3:7 preparation, large total volume, rectal Foley placement, 15–20-minute retention and close monitoring; it is not a routine home regimen.
Full-course cost-effectiveness -
A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.
Important safety and use flags
Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label. RECTAL MIXTURE: 20 ml/kg means total 3-parts-Duphalac + 7-parts-water mixture, equal to 6 ml/kg neat product. Giving 20 ml/kg neat Duphalac would be a 3.33-fold product-volume error. Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention. Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target. Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated. Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing. The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine. Hospital technique only: cleansing enema, correct dilution, atraumatic rectal Foley placement and 15–20-minute retention with serial neurologic, airway, hydration and electrolyte reassessment. The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review. Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence. Assessment sources +
Close
Dog
Oral lactulose adjunct for diagnosed hepatic encephalopathy or hyperammonaemia, alongside treatment of the cause and precipitating factors
7.0/10
Good
Details →
vetman assessment
Duphalac
×
667 mg/ml, oral solution, human medicine
Assessed clinical scope Dog · Oral lactulose adjunct for diagnosed hepatic encephalopathy or hyperammonaemia, alongside treatment of the cause and precipitating factors · By mouth
Care setting Veterinarian-directed hospital initiation or closely supervised outpatient care, with stool titration and neurologic, hydration and electrolyte reassessment.
vetman score
7.0/10
Good
Evidence confidence: Medium
Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026
Off-label use
A standard, mechanism-based HE adjunct whose clinical acceptance exceeds its veterinary trial evidence; use only with cause-directed treatment and stool/electrolyte titration.
Regulatory and scientific credibility 7.5/10
Exact Duphalac is transparent and human-authorised for HE, and veterinary consensus applies the same locally acting concentration, but the dog/cat indication is off-label and lacks a target-animal regulatory dossier.
Clinical efficacy 6.5/10
Lactulose is an established first-line HE adjunct with a clear mechanistic and consensus basis; however, the dog/cat review found no clinical trials, and the 17-dog multimodal cohort informs safety more than efficacy.
Safety and tolerability 7.0/10
Local action and mature product warnings are favourable, but HE uses repeated titration and often higher exposure in medically fragile patients, making diarrhoea, dehydration, electrolyte loss and sugar-residue review clinically important.
Clinical practicality 7.0/10
PO q8–12h titration is workable at home after stabilisation, but adherence, stool tracking and repeated adjustment are integral rather than optional.
Full-course cost-effectiveness -
A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.
Important safety and use flags
Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label. Use an accurately graduated oral syringe for animal-sized volumes. Do not assume that the human pack measuring cup can measure a small dog or cat dose accurately. Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention. Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target. Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated. Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing. The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine. Treat the liver/shunt cause and precipitating factors; lactulose is an adjunct, not definitive therapy. Do not give orally to a severely obtunded patient without a protected administration plan. The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review. Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence. Assessment sources +
Close
Dog
Oral treatment of constipation or clinically indicated facilitated defecation after exclusion of complete obstruction and perforation risk
7.9/10
Good
Details →
vetman assessment
Duphalac
×
667 mg/ml, oral solution, human medicine
Assessed clinical scope Dog · Oral treatment of constipation or clinically indicated facilitated defecation after exclusion of complete obstruction and perforation risk · By mouth
Care setting Veterinarian-directed outpatient treatment with an accurately graduated oral syringe, explicit stool endpoint and reassessment if response is absent after several days.
vetman score
7.9/10
Good
Evidence confidence: Medium
Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026
Off-label use
A well-supported same-strength osmotic laxative option with favourable safety and flexible dosing; this exact human product remains off-label and must not be used through complete obstruction or perforation risk.
Regulatory and scientific credibility 8.0/10
The exact human product has current official identity and Georgian/EU status, while a same-strength oral veterinary lactulose product has current dog/cat authorisation and a public assessment dossier; exact excipients and legal status still differ.
Clinical efficacy 8.0/10
A current dog/cat veterinary label and favourable generic assessment support the osmotic-laxative role and dose, but approval relied on an established reference product rather than new comparative outcome trials for exact Duphalac.
Safety and tolerability 8.0/10
Less than 2% systemic absorption, mature dog/cat label warnings and permitted pregnancy/lactation support favourable safety; gas and cramps are common, while excess causes diarrhoea, dehydration and electrolyte loss.
Clinical practicality 7.5/10
The liquid allows weight-based adjustment, food mixing and dose titration, but usually needs 2–3 daily administrations, may take 2–3 days and requires a suitably graduated oral syringe for small volumes.
Full-course cost-effectiveness -
A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.
Important safety and use flags
Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label. Use an accurately graduated oral syringe for animal-sized volumes. Do not assume that the human pack measuring cup can measure a small dog or cat dose accurately. Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention. Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target. Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated. Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing. The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine. No response after about 2–3 days, recurrent obstipation, vomiting, pain or systemic illness requires diagnostic reassessment rather than automatic dose escalation. The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review. Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence. Assessment sources +
Close
Cat
Hospital rectal retention-enema adjunct for acute hepatic encephalopathy when oral administration is unsafe or inadequate
5.9/10
Weak evidence support
Details →
vetman assessment
Duphalac
×
667 mg/ml, oral solution, human medicine
Assessed clinical scope Cat · Hospital rectal retention-enema adjunct for acute hepatic encephalopathy when oral administration is unsafe or inadequate · Into the rectum
Care setting Monitored hospital care after cleansing enema, with prepared dilution, rectal Foley retention technique, airway/mentation review and serial neurologic and fluid-electrolyte reassessment.
vetman score
5.9/10
Weak evidence support
Evidence confidence: Low
Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026
Off-label use
A plausible emergency HE adjunct supported by expert consensus, but invasive, preparation-sensitive and untested in controlled target-animal outcome trials.
Regulatory and scientific credibility 6.5/10
Exact product identity is strong, but rectal use is absent from its label and from the veterinary comparator label; support is professional consensus rather than a route-specific regulatory dossier.
Clinical efficacy 5.5/10
The acidification mechanism and small-animal emergency consensus are plausible, but no controlled dog/cat outcome trial or exact-product rectal study establishes neurologic benefit or superiority.
Safety and tolerability 6.0/10
Systemic exposure is minimal, but the exact rectal route lacks target-animal safety data and is used in unstable neurologic patients; mucosal technique, retention, fluid/electrolyte loss and aspiration/mentation context require close oversight.
Clinical practicality 5.5/10
The protocol is feasible in hospital but requires cleansing, exact 3:7 preparation, large total volume, rectal Foley placement, 15–20-minute retention and close monitoring; it is not a routine home regimen.
Full-course cost-effectiveness -
A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.
Important safety and use flags
Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label. RECTAL MIXTURE: 20 ml/kg means total 3-parts-Duphalac + 7-parts-water mixture, equal to 6 ml/kg neat product. Giving 20 ml/kg neat Duphalac would be a 3.33-fold product-volume error. Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention. Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target. Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated. Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing. The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine. Hospital technique only: cleansing enema, correct dilution, atraumatic rectal Foley placement and 15–20-minute retention with serial neurologic, airway, hydration and electrolyte reassessment. The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review. Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence. Assessment sources +
Close
Cat
Oral lactulose adjunct for diagnosed hepatic encephalopathy or hyperammonaemia, alongside treatment of the cause and precipitating factors
6.8/10
Situational / acceptable
Details →
vetman assessment
Duphalac
×
667 mg/ml, oral solution, human medicine
Assessed clinical scope Cat · Oral lactulose adjunct for diagnosed hepatic encephalopathy or hyperammonaemia, alongside treatment of the cause and precipitating factors · By mouth
Care setting Veterinarian-directed hospital initiation or closely supervised outpatient care, with stool titration and neurologic, hydration and electrolyte reassessment.
vetman score
6.8/10
Situational / acceptable
Evidence confidence: Low
Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026
Off-label use
A standard, mechanism-based HE adjunct whose clinical acceptance exceeds its veterinary trial evidence; use only with cause-directed treatment and stool/electrolyte titration.
Regulatory and scientific credibility 7.5/10
Exact Duphalac is transparent and human-authorised for HE, and veterinary consensus applies the same locally acting concentration, but the dog/cat indication is off-label and lacks a target-animal regulatory dossier.
Clinical efficacy 6.0/10
Lactulose is an established small-animal HE adjunct, but no veterinary drug trial was identified and direct feline outcome evidence is particularly sparse; consensus and mechanism therefore carry most of the score.
Safety and tolerability 7.0/10
Local action and mature product warnings are favourable, but HE uses repeated titration and often higher exposure in medically fragile patients, making diarrhoea, dehydration, electrolyte loss and sugar-residue review clinically important.
Clinical practicality 6.5/10
PO q8–12h is feasible but repeated accurately measured sweet viscous doses and stool titration can be demanding in cats, especially during neurologic illness.
Full-course cost-effectiveness -
A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.
Important safety and use flags
Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label. Use an accurately graduated oral syringe for animal-sized volumes. Do not assume that the human pack measuring cup can measure a small dog or cat dose accurately. Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention. Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target. Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated. Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing. The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine. Treat the liver/shunt cause and precipitating factors; lactulose is an adjunct, not definitive therapy. Do not give orally to a severely obtunded patient without a protected administration plan. The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review. Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence. Assessment sources +
Close
Cat
Oral treatment of constipation or clinically indicated facilitated defecation after exclusion of complete obstruction and perforation risk
7.9/10
Good
Details →
vetman assessment
Duphalac
×
667 mg/ml, oral solution, human medicine
Assessed clinical scope Cat · Oral treatment of constipation or clinically indicated facilitated defecation after exclusion of complete obstruction and perforation risk · By mouth
Care setting Veterinarian-directed outpatient treatment with an accurately graduated oral syringe, explicit stool endpoint and reassessment if response is absent after several days.
vetman score
7.9/10
Good
Evidence confidence: Medium
Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026
Off-label use
A well-supported same-strength osmotic laxative option with favourable safety and flexible dosing; this exact human product remains off-label and must not be used through complete obstruction or perforation risk.
Regulatory and scientific credibility 8.0/10
The exact human product has current official identity and Georgian/EU status, while a same-strength oral veterinary lactulose product has current dog/cat authorisation and a public assessment dossier; exact excipients and legal status still differ.
Clinical efficacy 8.0/10
A current dog/cat veterinary label and favourable generic assessment support the osmotic-laxative role and dose, but approval relied on an established reference product rather than new comparative outcome trials for exact Duphalac.
Safety and tolerability 8.0/10
Less than 2% systemic absorption, mature dog/cat label warnings and permitted pregnancy/lactation support favourable safety; gas and cramps are common, while excess causes diarrhoea, dehydration and electrolyte loss.
Clinical practicality 7.5/10
The liquid allows weight-based adjustment, food mixing and dose titration, but usually needs 2–3 daily administrations, may take 2–3 days and requires a suitably graduated oral syringe for small volumes.
Full-course cost-effectiveness -
A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.
Important safety and use flags
Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label. Use an accurately graduated oral syringe for animal-sized volumes. Do not assume that the human pack measuring cup can measure a small dog or cat dose accurately. Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention. Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target. Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated. Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing. The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine. No response after about 2–3 days, recurrent obstipation, vomiting, pain or systemic illness requires diagnostic reassessment rather than automatic dose escalation. The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review. Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence. Assessment sources +
Close
Administration route
By mouth, Into the rectum
Registration
Georgia
Yes, human
In force until 22 Sep 2031
Human (Ministry of Health, RAMA)
№ რ-045556, რ-046355
Verified on: 15 Oct 2026
EU
Yes, human
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified
Veterinary use of this exact human product is off-label. Constipation: 0.6 ml/kg/day PO, preferably divided into 2–3 doses; adjust to effect and allow about 2–3 days. Hepatic encephalopathy: start 0.25–0.5 ml/kg PO q8–12h and titrate to several soft, pudding-like stools, not diarrhoea. Acute HE rectal adjunct: after cleansing enema, use a 3:7 Duphalac:water mixture at 20 ml/kg total mixture, retain 15–20 minutes and reassess neurologic response. The 20 ml/kg is diluted mixture, not neat Duphalac.
Cat
Weight Constipation · By mouth Hepatic Encephalopathy · By mouth Hepatic Encephalopathy · Into the rectum
Any weight
0.6 ml/kg 0.25–0.5 ml/kg 6 ml/kg
Constipation · By mouth (total daily dose, preferably divided into 2–3 doses): Constipation/facilitated defecation. Adjust as needed; effect may require 2–3 days. The dose is a same-strength veterinary-label transfer; measure small feline volumes with an appropriately graduated oral syringe, not an unverified human cup.Hepatic Encephalopathy · By mouth (q8–12h initially; titrate to several soft pudding-like stools/day): Hepatic encephalopathy/hyperammonaemia adjunct. Direct feline outcome evidence is sparse; treat the cause and precipitating factors and titrate to stool response rather than a fixed high dose.Hepatic Encephalopathy · Into the rectum (3:7 Duphalac:water to 20 ml/kg total mixture; after cleansing, retain 15–20 min): Acute HE hospital adjunct. This is 20 ml/kg TOTAL MIXTURE made from 3 parts Duphalac plus 7 parts water, equivalent to 6 ml/kg neat product. The source does not provide a separate feline outcome trial.
Source:
Laxatract current SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Laxatract 667 mg/ml syrup for dogs and cats - current Summary of Product Characteristics
Veterinary Medicines Directorate, 2026
Dog
Weight Constipation · By mouth Hepatic Encephalopathy · By mouth Hepatic Encephalopathy · Into the rectum
Any weight
0.6 ml/kg 0.25–0.5 ml/kg 6 ml/kg
Constipation · By mouth (total daily dose, preferably divided into 2–3 doses): Constipation/facilitated defecation. Adjust as needed; effect may require 2–3 days. This dose is transferred from an authorised dog/cat 667 mg/ml veterinary lactulose product to the exact-strength human solution; use an appropriately graduated oral syringe.Hepatic Encephalopathy · By mouth (q8–12h initially; titrate to several soft pudding-like stools/day): Hepatic encephalopathy/hyperammonaemia adjunct. Treat the cause and precipitating factors; titrate stool endpoint and reduce for cramping, liquid diarrhoea, dehydration or electrolyte loss.Hepatic Encephalopathy · Into the rectum (3:7 Duphalac:water to 20 ml/kg total mixture; after cleansing, retain 15–20 min): Acute HE hospital adjunct. This is 20 ml/kg TOTAL MIXTURE made from 3 parts Duphalac plus 7 parts water, equivalent to 6 ml/kg neat product. Use an inflated rectal Foley catheter only with appropriate monitoring and technique.
Source:
Laxatract current SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Laxatract 667 mg/ml syrup for dogs and cats - current Summary of Product Characteristics
Veterinary Medicines Directorate, 2026
